Biotek-snakken — November 2024
-
Heldigvis er Teso ikke afvist, men de kræver blot flere data, så ja der er håb endnu og dagens kæmpe fald er klart en købsmulighed for den risikovillige.
-
Ascelia Pharma Announces Completion of Full Study Report Reinforcing the Successful Outcomes of Orviglance Phase 3 Study SPARKLE
Ascelia Pharma Announces Completion of Full Study Report Reinforcing the Successful Outcomes of Orviglance Phase 3 Study SPARKLE – ASCELIA
Ascelia Pharma AB (publ) (ticker: ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announce ...
(www.ascelia.com)
-
Ascelia Pharma AB (publ) (ticker: ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announced the completion of the Full Study Report for the pivotal Phase 3 Study for Orviglance
liver imaging drug candidate, which includes the previously announced strong results of primary endpoints. In addition, the results of secondary endpoints further reinforce the successful study outcomes and support the New Drug Application (NDA) process. -
Curasight: Clinical phase II trial of uPAR-PET in brain cancer patients published; data supports development of uTREAT for brain cancer https://news.cision.com/curasight/r/clinical-phase-ii-trial-of-upar-pet-in-brain-cancer-patients-published--data-supports-development-of,c4062536
-
Kvartalsrapport Q3: Framgångsrikt utfall av företrädesemission om 105 MSEK förlänger kassalikviditeten till sent 2025
https://www.ascelia.com/sv/ir-media-sv/finansiella-rapporter/
-
FINANSIELL UTVECKLING I SAMMANDRAG FÖR Q3 (jul-sep) 2024
• Rörelseresultatet uppgick till -17,8 MSEK (-21,4 MSEK)
• Vinst per aktie uppgick till -0,42 SEK (-0,63 SEK)
• Kassaflöde från den löpande verksamheten uppgick till -17,0 MSEK (-31,0 MSEK)
• Likvida medel inkl. kortfristiga placeringar uppgick till 95,7 MSEK (39,0 MSEK) -
En presentation för analytiker, investerare och media hålls idag 7 november kl. 10:00. Rapporten presenteras av företagets CEO Magnus Corfitzen, Deputy CEO Julie Waras Brogren och CSO Andreas Norlin. Presentationen kommer att hållas på engelska. Presentationen kan följas live via följande länk:
-
-
Genovis Interim Report January-September 2024
https://mb.cision.com/Main/1712/4062725/3100464.pdf
"Our Best Quarter in the Enzyme Business: Strong Growth and improved profitability"
-
Opsummering: regnskabet viser stærk underliggende vækst i enzym-forretningen, markant forbedret indtjening i Q3, strategisk positiv udvikling med fokus på kernekompetencer, plus der synes at være en klar retning i virksomheden (salg af antistof-forretningen og investering i Sequrna AB).
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind